国泰海通证券股份有限公司 关于宁波天益医疗器械股份有限公司 2025年半年度持续督导跟踪报告 | 保荐机构名称：国泰海通证券股份有限公司 | 被保荐公司简称：天益医疗 | | --- | --- | | 保荐代表人姓名：沈一冲 | 联系电话：021-38677509 | | 保荐代表人姓名：栾俊 | 联系电话：021-38676666 | —、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0次 | | 2.督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不限 于防止关联方占用公司资源的制度、募集资金管理 | 是 | | 制度、内控制度、内部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 每月查询 | | （2）公司募集资金项目进展是否与信息披露文件一 致 | 是 | | 4.公司治理督导情况 ...

Core Viewpoint - Tianyi Medical announced that its actual controller and major shareholder, Mr. Wu Bin, has released and re-pledged 4.5 million shares of the company, indicating a significant movement in shareholding structure and potential liquidity needs [1] Summary by Relevant Categories Shareholding Changes - Mr. Wu Bin released 4.5 million shares from pledge, which accounts for 37.50% of his total holdings and 7.63% of the company's total share capital [1] - The same number of shares, 4.5 million, has been re-pledged, maintaining the same percentage of his holdings and the company's total share capital [1] Pledge Details - The pledge initiation date is set for September 8, 2025, with a maturity date of September 3, 2030 [1] - The pledgee is CITIC Bank Co., Ltd. Ningbo Branch, and the purpose of the pledge is for personal funding needs [1]

证券代码： 301097 证券简称：天益医疗 公告编号：2025-048 宁波天益医疗器械股份有限公司 关于公司股东部分股份解除质押及再质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 宁波天益医疗器械股份有限公司（以下简称"公司"）于近日接到公司实际 控制人、持股5%以上股东吴斌先生的通知，其将所持本公司股份办理了解除质押 及质押业务，具体事项如下： 一、股东股份质押的基本情况 | | 是否为控股 | 本次解除 | 占其 | 占公 | | 是否 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 股东或第一 | 质押数量 | 所持 | 司总 | 是否为限 | 为补 | 质押起 | 质押到 | 质权人 | | 名称 | 大股东及其 | （股） | 股份 | 股本 | 售股 | 充质 | 始日 | 期日 | | | | 一致行动人 | | 比例 | 比例 | | 押 | | | | | 吴斌 | 是 | 4,500,000 | 37.50 | 7.63 ...

Core Viewpoint - Tianyi Medical's stock price has shown a significant increase of 25.00% year-to-date, indicating strong market performance despite a recent decline over the past 20 days [1] Company Overview - Tianyi Medical, established on March 12, 1998, is located in Ningbo, Zhejiang Province, and was listed on April 7, 2022 [1] - The company specializes in the research, production, and sales of medical devices, particularly in blood purification and ward care [1] - Revenue composition: Blood purification accounts for 59.05%, ward care for 34.08%, and other products for 6.87% [1] Financial Performance - For the first half of 2025, Tianyi Medical reported revenue of 227 million yuan, a year-on-year increase of 11.50%, while net profit attributable to shareholders was 9.48 million yuan, a decrease of 35.23% [1] - Cumulative cash distribution since the A-share listing amounts to 102 million yuan, with 87.5 million yuan distributed over the past three years [2] Shareholder Information - As of June 30, 2025, the number of shareholders is 4,196, a slight decrease of 0.31% from the previous period [1] - The average number of circulating shares per shareholder is 4,372, which has increased by 0.31% [1] - Major shareholders include Penghua Hongjia Mixed A and Yuanxin Yongfeng Ju You A, with some changes in holdings noted [2]

证券代码：301097 证券简称：天益医疗 公告编号：2025-047 宁波天益医疗器械股份有限公司 一、对外投资概述 宁波天益医疗器械股份有限公司（以下简称"公司"或"天益医疗"）于 2025 年 2 月 14 日召开第三届董事会第二十一次会议，审议通过了《关于对外投 资的议案》，同意通过新加坡全资子公司 PRIMACRON GLOBAL PTE. LTD.（潽莱 马克隆国际有限公司，以下简称"潽莱马克隆"或"买方"）向 BELLCO S.R.L. （以下简称"卖方"）收购其 CRRT-滤器业务资产（以下简称"标的业务"）。 具体内容详见公司于 2025 年 2 月 15 日在巨潮资讯网（www.cninfo.com.cn） 披露的《关于对外投资的公告》（公告编号：2025-008）。 二、对外投资进展情况 截至本公告披露日，子公司潽莱马克隆与卖方已完成标的业务的交割工作， 卖方已将标的资产注入其为本次收购之目的于 2025 年 2 月 28 日登记设立的全资 子公司 PRIMABELL S.R.L.（意大利潽莱马贝而有限公司），并已将意大利潽莱 马贝而有限公司的 100%的股份转让给潽莱马克隆。现将相关情 ...

证券代码：301097 证券简称：天益医疗 公告编号：2025-046 宁波天益医疗器械股份有限公司 关于开立募集资金专项账户 并签署募集资金四方监管协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 宁波天益医疗器械股份有限公司（以下简称"天益医疗"或"公司"）于 2024 年 12 月 27 日召开第三届董事会第二十次会议、第三届监事会第十七次会议审议 通过了《关于变更募集资金用途的议案》，同意变更募集资金用途，同意终止原 计划由子公司宁波泰瑞斯科技有限公司实施的募投项目"综合研发中心建设项 目"，并将其剩余全部募集资金变更用于新项目"泰国生产基地建设项目"；同 时同意将剩余超募资金全部调整用于"泰国生产基地建设项目"。本次变更事项 已经公司于 2025 年 1 月 13 日召开的 2025 年第一次临时股东大会审议通过。 截至本公告披露日，公司已完成在上海浦东发展银行宁波高新区支行募集资 金专项账户的开立及募集资金四方监管协议的签署，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意宁波天益医疗器械股份有限公司首 次公开发 ...

Core Viewpoint - The National Medical Products Administration (NMPA) has announced the cancellation of medical device registration certificates for two products from two companies, indicating regulatory actions in the medical device industry [1] Company Summaries - Shenzhen Huada Yinyuan Medical Technology Co., Ltd. had its registration certificate for an automatic medical PCR analyzer (Registration No. 20233221432) revoked [1] - Ningbo Tianyi Medical Instruments Co., Ltd. had its registration certificate for a disposable titration infusion device with needle (Registration No. 20163141122) revoked [1]

Group 1 - Tianyi Medical (301097) announced that the company and its wholly-owned subsidiaries and joint ventures have not provided guarantees to any off-balance sheet entities [1] - There are no overdue external guarantees, no guarantees involved in litigation, and no losses incurred due to guarantees resulting in adverse judgments [1]

Group 1 - The company Tianyi Medical announced that as of the disclosure date, the total guarantee amount provided to its subsidiaries is approximately 489 million RMB, accounting for 41.03% of the company's latest audited consolidated net assets [1] - The actual total guarantee balance provided by the company to its subsidiaries is about 153 million RMB, which represents 12.81% of the company's latest audited consolidated net assets [1] - As of the disclosure date, the total guarantee amount provided by subsidiaries to the company is 190 million RMB, accounting for 15.94% of the company's latest audited consolidated net assets [1] Group 2 - For the first half of 2025, the revenue composition of Tianyi Medical is as follows: medical devices account for 98.81%, while other sources account for 1.19% [2] Group 3 - As of the time of reporting, the market capitalization of Tianyi Medical is 2.6 billion RMB [3]

证券代码：301097 证券简称：天益医疗 公告编号：2025-045 宁波天益医疗器械股份有限公司 关于全资子公司为母公司提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、因公司经营发展需要，宁波天益医疗器械股份有限公司（以下简称"公 司"或"天益医疗"）拟与上海浦东发展银行股份有限公司宁波分行（以下简称 "浦发银行宁波分行"）签订《借款合同》，全资子公司宁波天益药业科技有限公 司（以下简称"天益药业"）拟与浦发银行宁波分行签订《最高额保证合同》，为 母公司天益医疗提供总金额人民币 1.9 亿元的连带责任保证。 2、本次担保的性质：连带责任保证。 3、本事项无需提交公司董事会及股东会审议，由相关子公司就担保事项履 行内部审批程序。 一、担保情况概述 因公司经营发展需要，天益医疗拟与浦发银行宁波分行签订《借款合同》， 全资子公司天益药业拟与浦发银行宁波分行签订《最高额保证合同》，为母公司 天益医疗提供总金额人民币 1.9 亿元的连带责任保证。 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第 2 ...